Bacterial vaginosis – a recurring problem

Women united in pain

pHyph has in clinical trials shown a high medical efficiency and a lower recurrence rate than placebo (13.9% Vs 27%)

Today bacterial vaginosis is usually treated with antibiotics, which is often a short-term solution. This is because the antibiotics kill both the bad, pathogenic bacteria and the good, important protective bacteria in the vaginal micro-environment.

Consequently, for around half of all those treated for bacterial vaginosis with antibiotics, the infection reappears within 90 days.

Another common side effect of antibiotic treatment is fungal infections.

The prevalence of bacterial vaginosis is currently 10-30%. Moreover, there is limited access to gynaecologists and doctors. When left untreated, more severe conditions can evolve, such as pelvic infections or pre-term delivery in pregnant women.

pHyph is expected to prevent new infections and will be an easily accessible over-the-counter option within Europe for anyone suffering from bacterial vaginosis.

The vaginal bacterial flora comprises health-related bacteria that protect the body against infections. When something happens that cause an imbalance in these bacterial populations, bacterial vaginosis can develop. Vaginal infections are stressful, both mentally and physically. Symptoms of bacterial vaginosis can be painful; vaginal discomfort, a burning sensation and an unpleasant odour. The infection therefore brings the risk of a major negative impact on a woman’s daily life, particularly in the case of recurrent infections.

Preliminary data from pre-clinical studies show that pHyph helps to restore the vaginal microbiome and so significantly reduces the risk of recurrent bacterial infections.

Nearly half a million treatments for bacterial vaginosis are used in Sweden every year.1 
A total of 75% are over-the-counter products without scientifically proven effect.2
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) database.

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time

The use of antibiotics drives the bacterial evolution towards antibiotic resistance.  By reducing the usage of antibiotics, resistance emergence may at least be delayed. One of the most important future changes we can make is to reduce the use of antibiotics. There is considerable demand for sustainable treatment options with an equivalent effect, without the risk of either resistance or antibiotic-related side effects. 

Globally, the prevalence of Bacterial Vaginosis is 23-27% among women.  
Misdiagnosis between Bacterial Vaginosis and Vaginal Candidasis are common. 
Reccurrence is the largest challenge today with the greatest demand for solution.

In Europe alone approximately 15-45 million women annually, suffer from vaginal infection. World wide, the need for an effective and easily accessible treatment among women is immense – and there is currently no antibiotic-free treatment that both prevents and cures.

kartaGedea Biotech AB
Medicon Village
Scheeletorget 1
223 81 Lund
Annette Säfholm, CEO
+46 (0) 708 - 91 86 81

Privacy Policy | Cookie Policy